{"analyses":[{"ciLowerLimit":"0.357","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.647","estimateComment":"The hazard ratio was estimated using a stratified Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Only primary and key secondary endpoints were formally tested; this endpoint was not formally tested.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.481","statisticalMethod":"stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.4","upperLimit":"96.1","value":"93.9"},{"groupId":"OG001","lowerLimit":"77.7","upperLimit":"86.4","value":"82.5"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.2","upperLimit":"88.5","value":"84.5"},{"groupId":"OG001","lowerLimit":"57.5","upperLimit":"69.3","value":"63.7"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.1","upperLimit":"75.4","value":"68.9"},{"groupId":"OG001","lowerLimit":"44.5","upperLimit":"59.0","value":"52.0"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.1","upperLimit":"65.6","value":"56.0"},{"groupId":"OG001","lowerLimit":"28.3","upperLimit":"49.1","value":"38.8"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"328"}],"units":"Participants"}],"description":"PD, PET: score 4 (uptake moderately \\> liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi \\>1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node \\>1.5 cm in any axis. New extranodal site \\>1.0 cm in any axis; if \\<1.0 cm, presence is unequivocal and attributable to lymphoma. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with FL and MZL were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL and MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL and MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"NUMBER","populationDescription":"Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Overall Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First","type":"SECONDARY","unitOfMeasure":"percent probability"}